PMID: 9181636May 1, 1997Paper

8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release

Psychopharmacology
G LucasU Spampinato

Abstract

In this study, both catalepsy and changes in extracellular levels of striatal dopamine (DA) and dihydroxyphenyl acetic acid (DOPAC) induced by the typical neuroleptic haloperidol (HAL) were simultaneously assessed, using intracerebral microdialysis in freely moving rats, in the presence of either the 5-HT1A agonist 8-OH-DPAT or the 5-HT2A/C antagonist ritanserin. HAL (1 mg/kg, SC) elicited a strong cataleptic state, reaching its maximal intensity (about 240 s) 2 h after the drug administration. This effect was paralleled by a long-lasting enhancement of striatal DA and DOPAC extracellular levels, reaching 230 and 350% of basal values, respectively. 8-OH-DPAT (0.1 mg/kg, SC) given 2.5 h after, and ritanserin (0.63 and 1.25 mg/kg, IP), given 15 min prior to HAL, significantly reduced the neuroleptic-induced catalepsy. However, both 5-HT agents failed to modify basal DA and DOPAC striatal outflow as well as the stimulatory effect of HAL on these parameters. It can thus be concluded that the anticataleptic effect of these compounds is not related to an alteration of DA release within the striatum.

Citations

Oct 28, 2005·Journal of Neural Transmission·B ScholtissenA F G Leentjens
Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Torgny H Svensson
Jul 16, 2003·European Journal of Pharmacology·Satoru NakaiTetsuro Kikuchi
May 7, 1998·European Journal of Pharmacology·H O KalkmanM D Tricklebank
Sep 28, 1999·European Journal of Pharmacology·L P Nucci-da-SilvaE A Del Bel
Sep 6, 2000·Pharmacology, Biochemistry, and Behavior·R CareyG De Palma
Mar 13, 2002·Pharmacology, Biochemistry, and Behavior·Philippe De DeurwaerdèreUmberto Spampinato
Aug 25, 2000·Progress in Neuro-psychopharmacology & Biological Psychiatry·R BruggemanW Timmerman
Oct 9, 2002·Progress in Neuro-psychopharmacology & Biological Psychiatry·Pattipati S Naidu, Shrinivas K Kulkarni
Oct 4, 2006·Nature Reviews. Drug Discovery·Anthony H V SchapiraGiora Davidai
Aug 27, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Robert M KesslerHerbert Y Meltzer
Oct 9, 2004·Behavioural Pharmacology·C P MüllerJ P Huston
Oct 19, 2011·Archaea : an International Microbiological Journal·Annarita PoliBarbara Nicolaus
Oct 19, 2010·Psychopharmacology·Sylvia Navailles, Philippe De Deurwaerdère
Jun 15, 2005·Journal of Neurochemistry·Philippe De DeurwaerdèreUmberto Spampinato
Mar 26, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·William Bara-JimenezThomas N Chase
Oct 20, 2006·Pharmacology & Therapeutics·K D Alex, E A Pehek
Feb 27, 2003·The European Journal of Neuroscience·Grégory PorrasUmberto Spampinato
Mar 26, 2016·Progress in Neurobiology·Philippe De Deurwaerdère, Giuseppe Di Giovanni
Mar 30, 2001·Journal of Psychopharmacology·R A BantickP M Grasby

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.